Amondys 45 (casimersen)

Treatment for rare Duchenne muscular dystrophy mutation approved by FDA

26 February 2021 | By Hannah Balfour (European Pharmaceutical Review)

The FDA conditionally approved Sarepta’s Amondys 45 (casimersen) after interim Phase III results indicated the treatment is reasonably likely to be of clinical benefit.